WO2001019376A3 - METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS - Google Patents

METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS Download PDF

Info

Publication number
WO2001019376A3
WO2001019376A3 PCT/US2000/024910 US0024910W WO0119376A3 WO 2001019376 A3 WO2001019376 A3 WO 2001019376A3 US 0024910 W US0024910 W US 0024910W WO 0119376 A3 WO0119376 A3 WO 0119376A3
Authority
WO
WIPO (PCT)
Prior art keywords
heparin
inflammations
inhibiting
cardiovascular diseases
treating cardiovascular
Prior art date
Application number
PCT/US2000/024910
Other languages
French (fr)
Other versions
WO2001019376A2 (en
Inventor
Thomas P Kennedy
Original Assignee
Charlotte Mecklenburg Hospital
Thomas P Kennedy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital, Thomas P Kennedy filed Critical Charlotte Mecklenburg Hospital
Priority to AU73701/00A priority Critical patent/AU763042B2/en
Priority to EP00961798A priority patent/EP1223948A2/en
Publication of WO2001019376A2 publication Critical patent/WO2001019376A2/en
Publication of WO2001019376A3 publication Critical patent/WO2001019376A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Methods for treating heart failure and diabetic vascular disease in patients are provided. A therapeutically effective amount of heparin is administered to a patient to inhibit NF-λB activity in the patient, and thus treating or preventing heart failure or diabetic vascular disease.
PCT/US2000/024910 1999-09-13 2000-09-12 METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS WO2001019376A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU73701/00A AU763042B2 (en) 1999-09-13 2000-09-12 Method of inhibiting NF-kappaB with heparin
EP00961798A EP1223948A2 (en) 1999-09-13 2000-09-12 Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39508199A 1999-09-13 1999-09-13
US09/395,081 1999-09-13

Publications (2)

Publication Number Publication Date
WO2001019376A2 WO2001019376A2 (en) 2001-03-22
WO2001019376A3 true WO2001019376A3 (en) 2001-12-13

Family

ID=23561619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024910 WO2001019376A2 (en) 1999-09-13 2000-09-12 METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS

Country Status (3)

Country Link
EP (1) EP1223948A2 (en)
AU (1) AU763042B2 (en)
WO (1) WO2001019376A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US7468358B2 (en) 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US20090036405A1 (en) * 2007-07-23 2009-02-05 University Of Utah Method for blocking ligation of the receptor for advanced glycation end-products (rage)
AU2013260101B2 (en) 2012-05-09 2016-10-27 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
GB201219696D0 (en) 2012-11-01 2012-12-12 Univ Liverpool Agents for the prevention and/or treatment of central nervous system damamge
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583865A1 (en) * 1992-08-17 1994-02-23 Transcend Therapeutics, Inc. Prevention and treatment of atherosclerosis
WO1998035691A1 (en) * 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583865A1 (en) * 1992-08-17 1994-02-23 Transcend Therapeutics, Inc. Prevention and treatment of atherosclerosis
WO1998035691A1 (en) * 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06-01), ZHAI GUANG-XI ET AL: "Preparation of low molecular weight heparin liposomal spray gel.", XP002165292, Database accession no. PREV199900005848 *
FRYER ALLISON ET AL: "Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 282, no. 1, 1997, pages 208 - 219, XP000997372, ISSN: 0022-3565 *
JORNESKOG GUN ET AL: "Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients.", VASA, vol. 22, no. 2, 1993, pages 137 - 142, XP000997375, ISSN: 0301-1526 *
KLEIMAN NEAL S ET AL: "Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial.", CIRCULATION, vol. 97, no. 19, 19 May 1998 (1998-05-19), pages 1912 - 1920, XP000997371, ISSN: 0009-7322 *
SACHE E ET AL: "PARTIALLY N DESULFATED HEPARIN AS A NON-ANTICOAGULANT HEPARIN SOME PHYSICO-CHEMICAL AND BIOLOGICAL PROPERTIES", THROMBOSIS RESEARCH, vol. 55, no. 2, 1989, pages 247 - 258, XP000997333, ISSN: 0049-3848 *
TAKAZAKURA E ET AL: "A NEW THERAPEUTIC METHOD OF DIABETIC GANGRENE RESULTS IN 10 CASES WITH CONTINUOUS INTRA-ARTERIAL INFUSION OF PROSTAGLANDIN E-1 INSULIN AND HEPARIN", DIABETES RESEARCH AND CLINICAL PRACTICE, no. SUPPL. 1, 1985, pages S545 - S546, XP000997398, ISSN: 0168-8227 *
THOURANI VINOD H ET AL: "Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 278, no. 6 Part 2, June 2000 (2000-06-01), pages H2084 - H2093, XP000997340, ISSN: 0002-9513 *
VAN DER PIJL JOHAN W ET AL: "Effect of danaparoid sodium on hard exudates in diabetic retinopathy.", LANCET (NORTH AMERICAN EDITION), vol. 350, no. 9093, 13 December 1997 (1997-12-13), pages 1743 - 1745, XP000990739, ISSN: 0099-5355 *
ZHONGGUO YIYAO GONGYE ZAZHI, vol. 29, no. 6, June 1998 (1998-06-01), pages 261 - 265, ISSN: 1001-8255 *

Also Published As

Publication number Publication date
WO2001019376A2 (en) 2001-03-22
AU7370100A (en) 2001-04-17
AU763042B2 (en) 2003-07-10
EP1223948A2 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
WO1997036609A3 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
WO2002060389A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
WO2001012122A3 (en) Method and system for treating cardiac arrest using hypothermia
TNSN00206A1 (en) Method for treating diabetes
SE9702860L (en) Use of a strain of Lactobacillus for the manufacture of a drug for reducing fibrinogen content in blood
HUP9800467A2 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
EP1733734A3 (en) Placental alkaline phosphatase to control diabetes
WO2001019376A3 (en) METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
AU4199197A (en) A bandage for fixating a cannula of a venous catheter to a skin surface part f a person
WO2004004664A3 (en) Methods for treating or preventing ischemic injury
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
GB9917405D0 (en) Methods of treatment and drug screening methods
WO2001091785A3 (en) Use of hyaluronidase for preventing and treating cardio vascular diseases
WO2002056837A3 (en) Inhibition of protein-phosphatases for the treatment of heart failure
WO2000013701A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
NZ513087A (en) Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
Thomas Treatment of acute stroke.
ZHUO et al. Comparison of incidence, mortality and treatment of acute myocardial infarction in hospitals in Japan and China
WO2001019359A3 (en) Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
Browne The case for intravenous magnesium treatment of arterial disease in general practice: review of 34 years of experience
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 73701/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000961798

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000961798

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 73701/00

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 2000961798

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000961798

Country of ref document: EP